Grants and funding for social organisations

NIDCD Research Grants for Translating Basic Research into Clinical Practice (R01 Clinical Trial Optional)

United States · US

Who can apply Public housing authorities/Indian housing authorities · Special district governments · State governments · Public and State controlled institutions of higher education · Small businesses · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · County governments · Independent school districts · Native American tribal organizations (other than Federally recognized tribal governments)

This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.

NCI Pathway to Independence Award (K99/R00 Clinical Trial Required)

United States · US

Who can apply City or township governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · State governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Native American tribal governments (Federally recognized) · Special district governments · Public housing authorities/Indian housing authorities · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Private institutions of higher education · For profit organizations other than small businesses · Public and State controlled institutions of higher education

The purpose of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition in order to help awardees to launch competitive, independent research careers.

NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)

United States · US

Who can apply Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · County governments · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · For profit organizations other than small businesses · City or township governments

The purpose of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition in order to help awardees to launch competitive, independent research careers.

Grants to compensate for the temporary cessation of fishing activities 2026 (FEMPA)

AUTONOMICA - CATALUÑA - DEPARTAMENT D'AGRICULTURA, RAMADERIA, PESCA I ALIMENTACIÓ ·

Who can apply PYME Y PERSONAS FÍSICAS QUE DESARROLLAN ACTIVIDAD ECONÓMICA

Agriculture, Fisheries and Food

Period: Jul 9, 2026 – —

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

United States · US

Who can apply State governments · Public housing authorities/Indian housing authorities · Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · County governments · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · City or township governments · Public and State controlled institutions of higher education · Independent school districts · Native American tribal organizations (other than Federally recognized tribal governments)

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)

United States · US

Who can apply Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · State governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education · Special district governments · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · City or township governments

This R61/R33 concept complements NIMHs suite of clinical trial NOFOs by supporting feasibility and infrastructure development (R61) followed by well-powered clinical trials (R33) to test the effectiveness of system interventions and strategies for improving the organization, delivery, coordination, and clinical and functional outcomes of mental health services. System interventions - which may span, for example, structural, policy, organizational, and interpersonal domains - attend to issues about the access, equity, engagement/utilization, value (cost/financing), management, or quality and safety of mental health services, with the goal of improved care processes and clinical and functional outcomes. Accordingly, the focus of system interventions may include a variety of care settings, such as health systems and organizations, mental health and community clinics, schools, and child welfare or juvenile justice systems

Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)

United States · US

Who can apply Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Small businesses · Public and State controlled institutions of higher education · County governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public housing authorities/Indian housing authorities · Special district governments · Independent school districts · Private institutions of higher education · For profit organizations other than small businesses

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). This NOFO is a key element of NIMHs set of NOFOs to support clinical trials research across the intervention development and testing pipeline. The NOFO supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services. This NOFO is intended to support trials that: address a significant problem, such that the findings have potential to inform practice; are adequately powered to definitively answer the primary research question(s), with well-justified hypotheses supported by pilot data; and are designed to examine questions regarding mediators and moderators of effects. Consistent with the NIMH experimental therapeutics approach, this NOFO is intended to support effectiveness trials that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). The collaborative R01 mechanism provides support for multisite trials when two or more sites are necessary for completion of the trial (e.g., to increase sample size, accelerate recruitment, or increase sample diversity and representation).

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

United States · US

Who can apply Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Native American tribal governments (Federally recognized) · Private institutions of higher education · Small businesses · City or township governments · Public housing authorities/Indian housing authorities · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · State governments · Public and State controlled institutions of higher education · For profit organizations other than small businesses

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this NOFO encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 Clinical Trial Required)

United States · US

Who can apply Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Independent school districts · For profit organizations other than small businesses · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public and State controlled institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · Private institutions of higher education · State governments · Native American tribal governments (Federally recognized)

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R01 Clinical Trial Required). As part of NIMH's clinical trials pipeline NOFOs, this announcement encourages pilot effectiveness studies focused on 1) optimizing the effectiveness of preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) developing and preliminary testing innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this NOFO is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.).

Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)

United States · US

Who can apply Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Private institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · State governments · County governments · Public and State controlled institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). As part of NIMH's clinical trials pipeline NOFOs, this announcement supports confirmatory efficacy testing of non pharmacological therapeutic and preventive interventions for mental disorders in adults and children that address unmet therapeutic needs, and are consistent with the NIMH emphasis on the experimental therapeutics approach. In this approach, clinical trials should be designed to increase knowledge of the relationship between underlying disease processes and the mechanisms of action through which any intervention produces therapeutic change.

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

United States · US

Who can apply Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Small businesses · Independent school districts · Public housing authorities/Indian housing authorities · County governments · State governments · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · City or township governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this NOFO encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to two years of support for evaluation of target engagement and establishment of intervention parameters, and up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)

United States · US

Who can apply Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Independent school districts · City or township governments · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Private institutions of higher education · State governments

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The NOFO also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

United States · US

Who can apply Native American tribal governments (Federally recognized) · Independent school districts · City or township governments · State governments · Small businesses · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · Public and State controlled institutions of higher education · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Special district governments · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification)

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)

United States · US

Who can apply Native American tribal governments (Federally recognized) · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · State governments · Small businesses · Special district governments · Private institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)

United States · US

Who can apply Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · Private institutions of higher education · Small businesses · Special district governments · Independent school districts · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized) · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · City or township governments

The goal of this funding opportunity announcement (FOA) is to fund meritorious vision-related research projects that involve secondary data analyses using existing database resources. The development of statistical methodology necessary for improving methods to analyze vision health data using existing vision data may also be proposed.

NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

United States · US

Who can apply Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · State governments · Private institutions of higher education · Special district governments · Public housing authorities/Indian housing authorities · Public and State controlled institutions of higher education · County governments · Independent school districts

The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

United States · US

Who can apply Public and State controlled institutions of higher education · Independent school districts · For profit organizations other than small businesses · Small businesses · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Native American tribal governments (Federally recognized) · City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Special district governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education

This Notice of Funding Opportunity (NOFO) solicits applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on early-stage development from prototyping to initial dissemination. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving research projects and other users throughout the development process must be included.This NOFO encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis is on uniqueness and potential impact on cancer research. In addition, all projects proposed in response to this NOFO must involve the following general attributes:Potential to advance driving cancer research projects and the cancer research field in generalNovel informatics capabilities for the targeted cancer research domainCompelling plans and processes for engaging end users to evaluate and apply the tool or resourceA realistic timeline and milestones for technology development

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

United States · US

Who can apply Public and State controlled institutions of higher education

The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

United States · US

Who can apply For profit organizations other than small businesses · Public housing authorities/Indian housing authorities · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Independent school districts · City or township governments · State governments · Special district governments · County governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification)

Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

United States · US

Who can apply Special district governments · City or township governments · Independent school districts · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized)

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

United States · US

Who can apply Small businesses · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · County governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized)

This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)

United States · US

Who can apply Private institutions of higher education · Public and State controlled institutions of higher education

The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions.Eligible institutions must award baccalaureate or advanced science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole.Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htmThis REAP Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this NOFO, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

United States · US

Who can apply Public and State controlled institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Native American tribal governments (Federally recognized) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · County governments · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Special district governments · State governments · Small businesses · City or township governments

Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

United States · US

Who can apply Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · Special district governments · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · County governments · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Private institutions of higher education · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education

Reissue of PAR-20-118. This Notice of Funding Opportunity (NOFO) encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO using the U01 mechanism supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion U19 FOA.